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Abstract
Background: The c-Myb transcription factor regulates differentiation and proliferation in hematopoietic cells, stem
cells and epithelial cells. Although oncogenic versions of c-Myb were first associated with leukemias, over
expression or rearrangement of the c-myb gene is common in several types of solid tumors, including breast
cancers. Expression of the c-myb gene in human breast cancer cells is dependent on estrogen stimulation, but
little is known about the activities of the c-Myb protein or what genes it regulates in estrogen-stimulated cells.
Methods: We used chromatin immunoprecipitation coupled with whole genome promoter tiling microarrays to
identify endogenous c-Myb target genes in human MCF-7 breast cancer cells and characterized the activity of c-
Myb at a panel of target genes during different stages of estrogen deprivation and stimulation.
Results: By using different antibodies and different growth conditions, the c-Myb protein was found associated
with over 10,000 promoters in MCF-7 cells, including many genes that encode cell cycle regulators or transcription
factors and more than 60 genes that encode microRNAs. Several previously identified c-Myb target genes were
identified, including CCNB1, MYC and CXCR4 and novel targets such as JUN, KLF4, NANOG and SND1. By studying
a panel of these targets to validate the results, we found that estradiol stimulation triggered the association of c-
Myb with promoters and that association correlated with increased target gene expression. We studied one target
gene, CXCR4, in detail, showing that c-Myb associated with the CXCR4 gene promoter and activated a CXCR4
reporter gene in transfection assays.
Conclusions: Our results show that c-Myb associates with a surprisingly large number of promoters in human
cells. The results also suggest that estradiol stimulation leads to large-scale, genome-wide changes in c-Myb activity
and subsequent changes in gene expression in human breast cancer cells.
Background
The importance of the c-Myb transcription factor in
breast cancer is closely linked to the response to estro-
gen [1]. Expression of the c-myb (MYB) gene is asso-
ciated with expression of estrogen receptors (ERs) in
breast tumors [2,3]. (Note: We use c-Myb and c-myb to
distinguish between the protein and gene, respectively.)
Regulation by ERs has been implicated in the post-tran-
scriptional regulation of c-myb gene expression [4] and
the c-myb gene is involved in recurrent translocations in
some breast tumors that are positive for expression of
ERs [5]. The c-myb gene is induced by activation of ERs
in breast cancer cell lines such as MCF-7 [6-8] and
c-Myb protein has been implicated in the regulation of
several genes important in breast cancer development
and progression, including BRCA1 [9], CXCL12 [10],
Mdm2 and p53 [11]. Although the expression of c-Myb
protein is important for estrogen-stimulated prolifera-
tion of breast cancer cells [6], the functions of c-Myb
and the target genes that it regulates in response to sti-
mulation of ERs have yet to be identified.
The c-myb gene is a cellular proto-oncogene from
which the v-myb oncogenes expressed by two avian leu-
kemia viruses are derived [12]. The v-myb oncogenes
transform hematopoietic cells in tissue culture and
induce leukemias in animals, and a mouse knockout of
c-myb leads to severe hematopoietic defects [13], which
has led many researchers to focus on the role of the
Myb proteins in hematopoietic cells. However, increas-
ing evidence has demonstrated an important role for
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ing breast and colon [14,15] and there are examples
where activated or rearranged alleles of c-myb play
important roles in epithelial tumors [14-17]. Since the
c-Myb protein is a DNA-binding transcription factor, its
oncogenic activity is likely linked to its ability to regu-
late specific target genes that affect cell proliferation or
tumorigenesis. Microarray studies have proved to be a
powerful tool for studying the activities of Myb proteins,
and they have identified dozens of genes that are
induced when c-Myb is ectopically over-expressed in
MCF-7 breast cancer cells and other cell types [18,19].
However, it is not clear whether those genes are directly
or indirectly regulated by c-Myb, whether they are also
regulated by c-Myb expressed at its normal levels, or
how their regulation is affected by stimulation of ERs or
other extra-cellular stimuli.
Chromatin immunoprecipitation (ChIP) offers an
approach for using specific antibodies to enrich for frag-
ments of the genome associated with a specific protein,
e.g. a transcription factor [20]. ChIP has proved to be
extremely powerful for studying epigenetic modifications
of genes undergoing activation or silencing or for con-
firming that specific transcription factors like c-Myb
associate with promoters in cells [10]. When the ChIP
samples are analyzed on a microarray of probes specific
for thousands of promoter regions (ChIP-on-chip), or
directly identified by sequencing the recovered DNA
fragments (ChIP-seq), the results can be used to map
the locations of transcription factor binding sites across
the whole genome [21]. However, one of the surprises
of such studies is the large number of promoters or
binding sites that have been identified. For example,
recent studies have shown that the transcription factor
Sall4 associates with 3,223 genes [22], c-Myc associates
with more than 4,000 genes [23], estrogen receptor
alpha associates with more than 10,000 genes [24] and
NFkappaB associates with more than 15,000 genes [25].
In this manuscript, we describe the use of ChIP-on-chip
approaches to map more than 10,000 binding sites for
c-Myb in MCF-7 cells. The collection includes nearly all
previously identified c-Myb target genes plus many new
targets, and the results have important implications for
how c-Myb regulates the proliferation of breast cancer
cells and how it participates in tumorigenesis.
Methods
Cells and culture conditions
MCF-7 cells (ATCC, Manassas, VA) were cultured at
37°C/5% CO2 in Dulbecco’s Modified Eagle’sM e d i u m
(DMEM; Invitrogen, Carlsbad, CA) supplemented with
10% (v/v) fetal bovine serum (Invitrogen, Carlsbad, CA).
For estrogen deprivation, cells (5×10
5 per/ml) were cul-
tured in phenol red free DMEM (Invitrogen, Carlsbad,
CA) supplemented with 5% charcoal stripped serum
(Invitrogen, Carlsbad, CA) for 48 hr. The deprived cells
were then stimulated by adding 10 nM beta-estradiol
(Sigma, St. Louis MO) for 24 hr. Changes in DNA
synthesis rates (data not shown) were used to verify that
the MCF-7 cells arrested and resumed growth under
these conditions, as reported previously [6].
Expression analysis, transcription assays, and
immunoprecipitation
Steady state RNA expression analysis, quantitative real-
time PCR (QPCR), transcriptional assays, immunoprecipi-
tation, and Western blots were performed as described
previously [18,26,27]. Primer pairs and Taqman probes are
listed in Additional file 1: Table S1 and Additional file 1:
Table S2. The CXCR4 reporter gene was generated by
cloning the region upstream of the CXCR4 start site into
the pGL2 basic vector (Invitrogen, Carlsbad, CA). For iso-
lation of cytoplasmic and nuclear fractions, MCF-7 cells
were harvested and resuspended in 5 pellet volumes
(500 μl) of cell lysis buffer (10 mM Tris-HCl pH 8.0,
85 mM KCl, 0.5% NP-40 plus protease inhibitors: 1 μM
each chymostatin, leupeptin, antipain, pepstatin-A; 1 mM
each phenylmethylsulfonyl fluoride and benzamidine) and
incubated on ice for 10 min. Lysates were passed twice
through a 26G 5/8” needle. Nuclei were collected by cen-
trifugation at 10,000 × g for 5 min then lysed in 500 μlo f
nuclear lysis buffer (50 mM Tris pH 8.0, 1% SDS, 10 mM
EDTA, plus protease inhibitors as described above). Under
these conditions, nuclear proteins such as histones were
found only in the nuclear fractions, while control cytoplas-
mic proteins such as GAPDH were only in the cytoplasmic
fraction (data not shown). Protein concentrations were
determined using Dc protein reagent (BioRad, Hercules,
CA) according to manufacturer’s instructions. Western
blots were developed using rabbit antiserum raised against
a bacterially expressed fragment of the c-Myb DNA bind-
ing domain [28].
Chromatin immunoprecipitation (ChIP) assays
A detailed protocol for the ChIP and ChIP-chip assays is
provided in the supplemental methods (see Additional
file 1). Briefly, ChIP assays were performed using stan-
dard methods [20] but shearing was performed in a
200 μl volume of 50 mM Tris pH 8.0 (Sigma, St. Louis,
MO) by adding 40 units of Micrococcal nuclease (USB,
Cleveland, Ohio) for 10 min at 37°C. EDTA (10 mM)
was used to stop the reaction and nuclei were lysed in
1% SDS. ChIP was performed with anti-Myb monoclo-
nal 1.1 antibodies (Millipore, Billerica MA), control
non-immune serum, anti-FLAG (Sigma, St. Louis MO)
or with a rabbit anti-peptide antiserum prepared by
using a peptide (HQGTILDNVKNLLEFAE) from the
c-Myb transcriptional activation domain as antigen
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and de-crosslinked, and the DNA was purified using
standard methods [20]. Primers used for QPCR reac-
tions using SYBR green (Biorad, Hercules CA) are listed
in Additional file 1: Table S3. ChIP assay results were
normalized for control genes (GAPDH) and control
non-immune antibodies. For ChIP-on-chip assays, DNA
(10 ng) was amplified according to manufacturer’sp r o -
tocol (http://www.affymetrix.com), but conditions were
controlled carefully to insure that antibody-specific
enrichment was preserved. Amplified DNA (6 μg) was
hybridized to Affymetrix promoter tiling array 1.0R and
data analysis was performed with Model-based Analysis
for Tiling (MAT) Arrays software using the P value of
1×10
-5 recommended by the authors [29]. Statistical
analysis was performed with PASW 17 (SPSS Inc., Chi-
cago Ill) software. Data were visualized in Integrated
Genome Browser (http://www.affymetrix.com). The
ChIP-on-chip data files have been deposited in the
NCBI GEO database (accession number: GSE18706).
Myb knockdown
Knockdown of c-myb was performed using an shRNA
expression vector kindly provided by Dr. Tom Gonda [6].
Briefly, cells were transduced with a lentivirus expressing
a doxycycline-inducible shRNA specific to c-myb or a
scrambled shRNA control. Expression of each shRNA
w a si n d u c e df o r2 4h rw i t h5μg/ml of doxycycline and
RNA levels were analyzed by QPCR as described above.
Myb lentivirus production
N-terminal FLAG-tagged human c-Myb [18] was cloned
into the unique PacI site of the pHR IRES GFP lentiviral
vector (kindly provided with packaging vectors by Dr.
Bruce Bunnell, Tulane University) downstream of an
EF1 alpha promoter. v-Myb was cloned in a similar
fashion except into the pLenti-6 vector (Invitrogen,
Carlsbad CA). Plasmids were transfected into 293 FT
cells (Invitrogen, Carlsbad CA) by calcium phosphate
transfection along with the lentiviral packaging plasmid
delta 8.9 and the pMD.G plasmid expressing the vesicu-
lar stomatitis virus glycoprotein. Supernatant was col-
lected at 24 hr and 48 hr. Ultrafiltration using an
Ambion Ultracell 100 kDa NMWL filter unit (Millipore,
Billerica MA) was used to concentrate viral superna-
tants. Cells were transduced in the presence of 8 μg/ml
of polybrene (Sigma, St. Louis MO) and sorted to enrich
for GFP+ transduced cells or selected with 5 μg/ml blas-
ticidin (Sigma, St. Louis, MO).
Results
c-myb expression is estrogen dependent
Several published studies suggest that c-myb RNA
expression is tightly regulated by estrogen and tamoxifen
in breast cancer cells [4,6,7], but the regulation of c-Myb
protein levels has been less well characterized. To estab-
lish a link between the activation of estrogen receptors
and the regulation of c-Myb protein levels and activity,
we arrested MCF-7 cells by first depriving them of estro-
gen, then stimulating them with beta-estradiol as pre-
viously described [6]. In a time-course experiment, c-myb
RNA levels increased about 2-fold relative to the estro-
gen-deprived cells by 6 hr (Figure 1B) and increased to
a b o u t5 - f o l db y2 4h r .T h u s ,c - myb RNA levels were
induced by beta-estradiol stimulation in MCF-7 cells.
These results agree very nicely with similar results pub-
lished by others [4,6,7].
However, we got different results when checking the
expression of c-Myb protein. As shown in Figure 1B,
there was little to no change in c-Myb protein levels in
cells that were deprived (Depr) by growing them in
estrogen-free medium or stimulated (Stim) for 24 hr
with beta-estradiol. In addition, similar amounts of
c-Myb protein were recovered in the crude cytoplasmic
(C) and nuclear (N) extracts isolated from the two cell
types. This result is different than hematopoietic cells,
in which c-Myb protein is largely or exclusively in the
nucleus [30]. Time course experiments showed little or
no difference in c-Myb protein levels in any of the time
points (similar results were obtained with multiple anti-
c-Myb antibodies, data not shown). This suggests that
the steady-state level of c-Myb protein remains fairly
constant in MCF-7 cells, and also that c-Myb does not
undergo gross changes in sub-cellular localization dur-
ing or after estrogen stimulation, despite the increased
levels of c-myb RNA. Thus, if increased levels of c-myb
mRNA lead to increased synthesis, it must be balanced
by faster turnover of c-Myb protein in the estrogen-
stimulated cells. We conclude that c-Myb protein is
present at similar and fairly constant levels in both
estrogen-deprived and stimulated MCF-7 cells, raising
the possibility that it could regulate different sets of tar-
get genes in the two conditions.
Identification of c-Myb target genes in MCF-7 cells
Microarray experiments have shown that overexpression
of the normal c-Myb protein or the oncogenic derivative
v-Myb protein from Avian Myeloblastosis Virus in
MCF-7 cells leads to the activation of different sets of
target genes [18] and that c-Myb expression is necessary
for beta-estradiol-induced proliferation of MCF-7 cells
[6]. We turned to genome-wide Chromatin Immunopre-
cipitation (ChIP) coupled with promoter microarrays, or
ChIP-on-chip assays, to identify c-Myb target genes that
could be involved in regulating the proliferation of
MCF-7 cells. This approach had the advantage of fol-
lowing endogenous genes and did not depend on the
over-expression of c-Myb, which could affect c-Myb
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have been identified in a variety of different cell types
and culture conditions and the expression of the c-myb
gene is regulated by estrogen in MCF-7 cells, although
t h e r ei ss o m ee v i d e n c et h a tc - myb gene regulation may
be due to non-genomic pathways that do not involve
the classical estrogen receptors [31]. Therefore, we set
up our experiments to be as inclusive as possible and
included cells that had been estrogen deprived and then
stimulated with beta-estradiol for 24 hr as well as cells
that were grown to high density in complete medium.
Briefly, MCF-7 cells grown under the two conditions
were treated with formaldehyde to cross-link DNA-
protein complexes. After purification, fragmented chro-
matin complexes were immunoprecipitated with two
different anti-Myb antibodies, (1493 or Ab1.1, also
referred to as VKN or Upstate antibodies, respectively)
or with a control IgG antibody. Purified DNA was
amplified, labeled and hybridized to Affymetrix Promo-
ter Tiling arrays with probes spanning 10 kb regions
around the promoters of approximately 25,000 known
human genes. This approach identified a combined
8,813 target genes with the first antibody in the two dif-
ferent growth conditions, and combined 5,112 targets
with the second antibody in the two conditions, for a
total of 11,290 statistically significant (P = 1×10
-5)b i n d -
ing sites enriched by one or more of the Myb antibodies
in one or both of the growth conditions in MCF-7 cells
(Figure 2A). This P value was determined empirically,
based on recommendations by the authors of the analy-
sis software [29] and is intended to be inclusive in order
to detect as many Myb binding sites as possible. Analy-
sis of the enriched DNA sequences showed that
approximately 75% of the sites contained predicted
c-Myb binding sites (data not shown). The identified
genes included previously described c-Myb targets
BRCA1, CCNB1, CCNE1, CXCR4, KIT, MYB and MYC
and other genes that have not been previously identified
as Myb-regulated genes, including ELK4, EPB41, JUN,
KLF4, NANOG and SND1, as well as more than 60
genes that encode microRNAs (see Additional file 1:
Figure S1). A core group of 2,635 target genes were
identified by both antibodies in one or both of the
growth conditions.
ChIP and QPCR validate ChIP-on-chip results
We chose a panel of 5 genes to validate some of the
results from the ChIP-on-chip assays. Our laboratory
previously identified the CXCR4 gene as a potential
Myb target gene after it was up-regulated in MCF-7
cells expressing the v-Myb or c-Myb transcription fac-
tors [18]. JUN encodes a component of the transcription
f a c t o rA P - 1 ,a n di s ,l i k ec - M y b ,ap r o t o - o n c o g e n e .
EPB41 encodes the erythrocyte protein band 4.1, which
was first identified in erythroid cells but is also
expressed on other normal and cancer cell types [32,33].
CCNB1 encodes the cell cycle regulator Cyclin B1 and
has been previously identified as a c-Myb target gene in
hematopoietic cells [34] and KLF4 encodes the zinc fin-
ger transcription factor Kruppel-like factor 4, which is
important in the regulation of hematopoiesis and in the
production of induced pluripotent stem cells [35,36].
We used a conventional ChIP assay, followed by
Quantitative real-time PCR (QPCR) with primers from
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Figure 1 c-Myb expression is estrogen regulated. (A) MCF-7 cells
were deprived of estrogen for 48 hr then stimulated with 10 nM
17-beta-estradiol for 6, 12 or 24 hr. Quantitative real time PCR
(QPCR) was used to measure the levels of c-myb RNA during the
deprivation and stimulation protocol. Error bars show standard
deviation in triplicate PCR reactions, and results are relative to the
estrogen-deprived cells. (B) Western blot with anti-c-Myb and anti-
beta-actin antibodies of estrogen-deprived (Depr) or stimulated
(Stim) MCF-7 cells, divided into cytoplasmic (C) or nuclear (N)
fractions as described in Methods.
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the c-Myb binding sites in these selected genes. As
shown in Figure 2B, the promoters of the CXCR4 and
KLF4 genes were enriched approximately 35-fold and
30-fold by the Myb antibodies, respectively. The JUN,
EPB41, and CCNB1 binding sites were enriched 5 to 10
fold compared to the control gene (GAPDH) or the
background detected using the control non-specific
immunoglobulin (IgG). In addition to these five genes,
we also tested 10 additional randomly chosen genes
identified in the ChIP-on-chip assays, and all but one
was enriched and validated in the conventional ChIP
assay (data not shown). Based on these results, we con-
clude that most of the binding sites identified in the
ChIP-on-chip assays are likely to be bona fide c-Myb
targets, suggesting that c-Myb occupies thousands of
promoters in MCF-7 cells. Details about all of the bind-
ing sites we identified are provided in the supplemental
materials (see Additional file 2, Additional file 3, Addi-
tional file 4, Additional file 5 and Additional file 6) and
the complete data sets have been deposited in the NCBI
GEO database (accession number: GSE18706).
In addition to c-Myb, MCF-7 cells also express several
Myb-related proteins, including A-Myb (MYBL1) and B-
Myb (MYBL2), which are also induced following beta-
estradiol treatment [7]. Although we used two different
antibodies that should be specific for c-Myb, there was a
possibility that we had detected one or both of the other
Myb proteins in our assays. As an extra level of valida-
tion, we transduced MCF-7 cells with a lentivirus
expressing FLAG epitope-tagged c-Myb and used anti-
FLAG antibodies in the ChIP assay protocol. As shown
in Figure 2C, ChIP assays using anti-FLAG antibodies
enriched for the CXCR4 promoter approximately 100-
fold, and for the JUN, EPB41, CCNB1, and KLF4 pro-
moters about 10-fold. Control genes (GAPDH) and
other regions of the CXCR4 promoter that do not con-
tain c-Myb binding sites were not enriched in these
assays (data not shown). We conclude that the ChIP
assays are specific and identify bona fide c-Myb targets
in MCF-7 cells.
c-Myb binding specificity is affected by beta-estradiol
treatment
We also analyzed our ChIP-on-chip data to see if c-Myb
associated with the same promoters in the two growth
conditions, confluent cells vs. cells that had been estro-
gen-deprived then stimulated with beta-estradiol. As
summarized in Figure 3A, c-Myb was bound to 5,490
promoters in the confluent cells, 3,203 promoters in the
stimulated cells, and 2,597 promoters in both conditions
(these numbers are derived by pooling the results
obtained with the two antibodies in the two different
growth conditions, which were analyzed separately). The
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Figure 2 ChIP on chip identifies c-Myb target genes.( A )C h I P -
on-chip was performed with anti-Myb antibodies 1493 and 1.1
using chromatin from MCF-7 cells that were deprived of estrogen
for 48 hr followed by 24 hr of estrogen stimulation or grown to
high density. The Venn diagram summarizes the statistically
significant (P = 1×10
-5) binding sites identified by each antibody in
at least one of the two growth conditions. The complete list of
binding sites is provided in Additional file 2, Additional file 3,
Additional file 4, Additional file 5 and Additional file 6. (B) ChIP with
anti-c-Myb antibodies. MCF-7 cells were subjected to chromatin
immunoprecipitation with anti-c-Myb antibodies. Enrichment for the
CXCR4, JUN, EPB41, CCNB1, and KLF4 promoters was assessed by
QPCR. Fold enrichment was calculated relative to a control gene
(GAPDH) and a control antibody (mouse non-specific IgG). Error bars
show standard deviation of triplicate PCR reactions. (C) Conventional
ChIP with anti-FLAG antibodies was performed on MCF-7 cells
transduced with FLAG epitope-tagged c-Myb, using anti-FLAG
antibodies. Fold enrichment was calculated as described above.
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tion of c-Myb occurs, with the protein bound to largely
different sets of target genes in the two growth
conditions.
W eu s e dt h ep a n e lo fg e n e sw ei d e n t i f i e di nF i g u r e2
to characterize changes in c-Myb specificity during
estrogen depletion or stimulation with beta-estradiol. As
shown in Figure 3B we did not detect significant levels
of c-Myb at any of the promoters during estrogen depri-
vation, although c-Myb protein was abundantly
expressed (Figure 1). Upon beta-estradiol stimulation we
observed a marked increase of c-Myb binding at the
JUN and EPB41 promoters (Figure 3B) and a smaller,
but still significant 5 to 10-fold enrichment of the
CXCR4, CCNB1, and KLF4 gene promoters. Thus,
although c-Myb protein was expressed equally during
estrogen deprivation and stimulation (Figure 1), it was
only detectable at the target gene promoters in the latter
cells. To extend our results we repeated this experiment
using the MCF-7 cells expressing FLAG-tagged c-Myb.
W e s t e r nb l o ta n a l y s i sd e m o n s t r a t e dt h a tF L A G - t a g g e d
c-Myb was expressed in transduced cells (see Additional
file 1: Figure S2). As shown in Figure 3C, estrogen sti-
mulation also led to an increased enrichment of all the
target gene promoters when anti-FLAG antibodies were
used for the ChIP assays.
These results are somewhat paradoxical. The Western
blot (Figure 1B) showed that c-Myb protein is stably
expressed during estrogen starvation, but the ChIP
assays were unable to detect c-Myb bound to any of the
target genes we tested under those conditions. In con-
trast, c-Myb association with the promoters greatly
increased following beta-estradiol stimulation. The
results suggest that stimulation leads to large changes in
the activity of c-Myb and its ability to associate with
specific target gene promoters. Our analysis showed that
only about 30% of the identified c-Myb binding sites
also contained potential sites for the binding of ERs
(data not shown), suggesting that the mechanism affect-
ing changes in c-Myb activity may be due to non-
genomic effects or the activation of signaling pathways
that lead to changes in c-Myb protein activity or target-
ing. Interestingly, ERalpha has been shown to be impor-
tant in the regulation of c-myb gene expression [6],
suggesting that multiple estrogen-responsive pathways
contribute to the regulation of c-Myb protein levels and
its activity.
A disconnect between c-Myb binding and gene activation
To address the impact of c-Myb binding to the target
gene promoters, we performed a time course experi-
ment with cells deprived of estrogen or treated with
beta-estradiol for up to 24 hr and analyzed the relative
expression of each of the genes characterized above.
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Figure 3 c-Myb activity is estrogen stimulated. (A) Comparison
of ChIP-on-chip results obtained with MCF-7 cells that were
deprived of estrogen for 48 hr followed by 24 hr of estrogen
stimulation (Stimulated) or grown to high density (Confluent). The
Venn diagram summarizes the statistically significant (P = 1×10
-5)
binding sites identified in the two growth conditions. The complete
list of binding sites is provided in Additional file 2, Additional file 3,
Additional file 4, Additional file 5 and Additional file 6. (B) ChIP was
performed on MCF-7 cells deprived of estrogen for 48 hr (gray bars)
or deprived and then stimulated with 10 nM 17-beta-estradiol for
24 hr (black bars). Chromatin complexes were immunoprecipitated
with anti-c-Myb 1.1 antibodies. Enrichment for the CXCR4, JUN,
EPB41, CCNB1, and KLF4 promoters were measured by QPCR. Error
Bars represent standard deviation of triplicate PCR reactions. (C)
ChIP was performed as in (B) using MCF-7 cells expressing FLAG-
tagged c-Myb and chromatin complexes were immunoprecipitated
with anti-FLAG antibodies. Enrichment for the CXCR4, JUN, EPB41,
CCNB1, and KLF4 promoters were measured by QPCR. Error Bars
represent standard deviation of triplicate PCR reactions.
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displayed a different pattern of expression in the time
course experiment. Compared to the estrogen-deprived
cells, the CCNB1 gene showed no response at 6 hr but
was about 5-fold induced at 12 hr and returned to base-
line expression by 24 hr (Figure 4A). CXCR4 was about
3-fold induced at 6 and at 12 hr, but was nearly 7-fold
induced by 24 hr. JUN showed no induction at 6 or
12 hr, but was strongly activated at 24 hr. The KLF4
gene showed no response at 6 hr, but was induced
4-fold by 12 hr and more than 8-fold at 24 hr. Only the
EPB41 gene failed to be activated following beta-estra-
diol stimulation. Although c-Myb was bound to each of
these target promoters after addition of beta-estradiol,
the genes responded quite differently, suggesting that, at
least for some genes, changes in the binding of c-Myb
to the promoters was not sufficient to cause increased
expression.
Because the kinetics of activation of the genes was so
different, we used an shRNA knock down strategy to
test whether c-Myb was required for their expression.
We introduced a lentivirus harboring a doxycycline-
inducible shRNA [6] targeting the c-myb mRNA (kindly
provided by T. Gonda) into the MCF-7 cells, then tested
the effects of doxycycline-induced knock down of
c-Myb. The shRNA construct efficiently knocked down
c-Myb protein expression after 24 hr of doxycycline
treatment relative to the scrambled control (see Addi-
tional file 1: Figure S2) and c-myb RNA levels decreased
approximately 70% (Figure 4B). Levels of the CCNB1,
CXCR4, JUN and KLF4 target gene mRNAs were also
dramatically reduced by the shRNA targeting c-myb
(Figure 4B). The EPB41 RNA, which was not inducible
by beta-estradiol (panel A), was also not affected by the
c-myb shRNA. The scrambled control shRNA did not
lead to significant decreases in any of the RNAs. These
results confirm that c-Myb expression is required to
maintain expression of the CCNB1, CXCR4, JUN and
KLF4 genes in MCF-7 cells, suggesting that these genes
are endogenous targets of c-Myb. The EPB41 gene has a
c-Myb binding site, but its expression is not significantly
regulated by estrogen deprivation or beta-estradiol sti-
mulation or dependent on c-Myb in these cells.
Binding sites for c-Myb in the CXCR4 promoter
To further confirm the ChIP results, we decided to
investigate the regulation of one c-Myb target gene in
more detail. CXCR4 is the receptor for the chemokine
SDF-1, is important in the metastatic potential of estro-
gen receptor positive ovarian and breast cancer [37,38]
and is linked to poor prognosis in a variety of tumor
types and leukemias [39-41]. We previously identified
CXCR4 as a potential c-Myb target gene in microarray
experiments using MCF-7 cells [18,19]. The promoter of
the CXCR4 gene has been characterized, but was not
described as having binding sites for c-Myb [42]. How-
ever, there are at least 10 potential c-Myb binding sites
in the CXCR4 promoter, although some contain mis-
matches from the normal consensus (see Additional file
1: Table S4). Since our ChIP results showed that c-Myb
binds the CXCR4 promoter in human cells, we decided
to characterize the interactions more directly.
Previous work from our laboratory [18] showed that
CXCR4 gene expression increased substantially follow-
ing ectopic expression of either c-Myb or its oncogenic
derivative v-Myb (Figure 5A). We isolated and analyzed
the human CXCR4 gene promoter and used it to assemble
a luciferase-based reporter gene construct (Figure 5B).
As shown in Figure 5C, both c-Myb and v-Myb acti-
vated the reporter gene when they were co-transfected
into HEK293 cells (which have very low endogenous
c-Myb levels) but v-Myb had more activity at the
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Myb and v-Myb regulate the expression of the CXCR4
gene by directly binding its promoter. Finally, to con-
firm that v-Myb also interacted with the endogenous
CXCR4 promoter in MCF-7 cells, we generated MCF-7
cells expressing a FLAG epitope-tagged version of
v-Myb (Additional file 1: Figure S2), then did a ChIP
assay using anti-FLAG antibodies as described in the
previous sections. As shown in Figure 5D, the FLAG-
tagged v-Myb bound to the CXCR4 promoter, but not
to an endogenous control promoter, GAPDH. Taken
together, these results confirm that the CXCR4 gene is
regulated by both normal and oncogenic variants of
c-Myb in human cells.
Discussion
c-Myb binds to thousands of endogenous target genes
We performed a genome wide analysis to identify c-Myb
target genes and although we demonstrated that c-Myb
is bound to a substantial fraction of the genes, our num-
bers are consistent with other similar studies. ChIP-on-
chip or ChIP followed by high throughput sequencing
(ChIP-seq) has been performed with a variety of tran-
scription factors such as c-Myc, Sall4, estrogen receptor
alpha and NFkappaB [22,24,25,43]. Genome wide ana-
lyses identified approximately 8,000, 3,200, 10,000 and
15,000 binding sites for these four transcription factors,
respectively. The results suggest that many transcription
factors, including c-Myb, are bound to large and diverse
sets of target genes. To validate our ChIP-on-chip
results, we analyzed 15 of the identified binding sites
using conventional ChIP assays, and were able to con-
firm the association with c-Myb for 14 (>90%) of them.
However, the expression of at least some of the identi-
fied genes was not dependent on expression of c-Myb.
T h eo n ee x a m p l et h a tw ei d e n t i f i e dw a st h eE P B 4 1
gene, which has a c-Myb binding site identified by
ChIP-on-chip and validated by conventional ChIP,
although the gene was not induced by beta-estradiol sti-
mulation (which leads to higher expression of c-Myb)
and its expression did not decline when c-Myb expres-
sion was knocked down with an shRNA (Figure 4).
A disconnect between c-myb RNA and c-Myb protein
expression
The expression of c-myb RNA is affected by beta-estra-
diol stimulation, which relieves the transcriptional
attenuation in intron I of the c-myb gene [6]. We found
that beta-estradiol stimulation led to increased levels of
c-myb RNA, although c-Myb protein levels remained
constant and did not change accordingly. This unex-
pected result suggests that c-Myb protein levels may be
regulated through a complex mechanism in MCF-7
cells. The c-Myb protein has sites of ubiquitinylation
and sumoylation that can have a dramatic effect on its
turnover and degradation rate [44-46]. Activation of
Wnt signaling pathways can lead to phosphorylation,
ubiquitinylation and degradation of c-Myb [47]. There is
evidence of a link between the Wnt signalling and estro-
gen receptor pathways [48], and Wnt1 has been
reported to be an estrogen receptor response gene [49],
so it is possible that estrogen stimulation can simulta-
neously induce the expression of c-myb RNA and also
lead to more rapid turnover and degradation of c-Myb
protein, and that c-Myb protein could be stabilized in
estrogen-deprived cells. This type of mechanism could
explain why c-Myb protein levels appear to remain con-
stant, even in estrogen-deprived MCF-7 cells.
Estrogen stimulation affects c-Myb DNA binding to target
genes
One of the most striking results from our study was the
finding that c-Myb association with many target genes was
greatly enhanced by beta-estradiol stimulation. This effect
was seen both for endogenous c-Myb, and also for FLAG-
tagged c-Myb expressed from a lentivirus vector (Figure 3).
For example, enrichment of the CXCR4, JUN and CCNB1
promoters all increased at least 10-fold following beta-
estradiol stimulation, suggesting that more c-Myb was
associated with the promoters of these genes in the stimu-
lated cells. These results could be explained by a lack of c-
Myb binding to target gene promoters in estrogen-
deprived cells. However, we found no significant change in
c-Myb protein levels in the different growth conditions, so
a change in binding would imply that c-Myb either failed
to bind DNA or was relocated away from the active chro-
matin during estrogen depletion.
The c-Myb protein has not been reported to interact
directly with Estrogen Receptors alpha or beta, although
it does interact with a large collection of transcription
factors and transcriptional co-activators [50], so there
remains a possibility that the nuclear estrogen receptors
could interact directly with c-Myb to affect its activity
or to influence which genes c-Myb associates with. Our
results suggest that c-Myb association with specific pro-
moters is regulated and that c-Myb may associate with
different subsets of target promoters in cells that are
confluent compared to cells that are stimulated with
beta-estradiol. This regulation could occur through
changes in c-Myb protein, such as post-translational
modifications, or changes in the expression or activity of
proteins that cooperate with c-Myb at specific promo-
ters. The results presented here provide the first evi-
dence of large scale regulation of c-Myb activity and
specificity in cells that are in different growth phases,
suggesting that c-Myb is regulated largely by protein-
protein interactions that help guide it to different target
genes in different types of cells.
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eral signaling pathways through the alternative estrogen
receptor GPER [51,52], so it is possible that these or
other similarly-activated pathways are involved in the
regulation of c-Myb DNA binding or localization during
estrogen stimulation in MCF-7 cells. There is some evi-
dence that the c-myb gene may be regulated by so-
called non-genomic or alternative estrogen receptors
[31]. Thus, changes in signal transduction pathways,
perhaps regulated by these non-classical estrogen recep-
tors, could lead to changes in c-Myb protein activity
and/or specificity. Our results using ChIP assays provide
the first evidence of large scale changes in c-Myb DNA
binding activity occurring in response to cellular signals,
and provide a new platform for studies of c-Myb regula-
tion in future studies.
Implications for the mechanisms of gene regulation
by c-Myb
Our results raise the question of why c-Myb and other
transcription factors are associated with so many pro-
moters, especially since our own microarray studies only
identified about 250 genes whose expression levels chan-
ged when c-Myb or v-Myb were over-expressed in
MCF-7 cells [18,19]. One explanation could be the large
number of intra- and inter-chromosomal interactions
detected by long-range cross-linking methods [53],
which detect interactions between promoters and distant
regulatory elements. In some cases, a single promoter
can make dozens of interactions with other parts of the
chromosome, or even other chromosomes [54]. The
ChIP-on-chip methodology we used only detects promo-
ters, since only probes for the promoters are on the til-
ing arrays that we used. However, we could be detecting
long-range interactions between c-Myb bound at distant
sites interacting with the promoters that we detect.
Recent findings showing that c-Myb binds both to pro-
moters and distant enhancerss u p p o r t st h i sv i e w[ 5 5 ] ,
and implicates c-Myb in the regulation of long-range
interactions between promoters and distant regulatory
elements. The use of more advanced techniques will be
required to resolve these issues and to understand
which types of signals and regulators play a role in con-
trolling the activity of c-Myb.
Conclusions
Our results show that c-Myb associates with a surpris-
ingly large number of promoters in human cells. The
results also suggest that beta-estradiol stimulation leads
to large-scale, genome-wide changes in c-Myb activity
and subsequent changes in gene expression in human
breast cancer cells. These results have important impli-
cations for understanding how signaling pathways affect
the activity of transcription factors like c-Myb, and for
understanding how stimulation of estrogen receptors,
both classical and non-classical, affects so many genes in
breast cancer cells. Our results suggest that c-Myb activ-
ity is dramatically different in cells that are in different
growth conditions, and highlight the necessity for future
studies to include characterization of both RNA levels
as well as protein activity in order to unmask the role of
c-Myb in cancer and normal cells.
Additional material
Additional file 1: This file contains information about the custom
and commercial primer sets used for QPCR assays (Tables S1, S2
and S3), and the locations and sequences of the putative Myb
binding sites in the human CXCR4 gene promoter (Table S4). Also
included is Figure S1, which diagrams the Myb binding sites identified in
the ChiP-on-chip assays for several target genes, and Figure S2, which
shows control Western blots confirming the expression of some of the
transduced Myb proteins described in this study and the effects of the
shRNA knockdowns, which is included as supplemental data since it
confirms results previously published by others [6].
Additional file 2: The ChIP-on-chip results obtained using confluent
cells and antibody 1.1 (tab-delimited text file).
Additional file 3: The ChIP-on-chip results obtained using confluent
cells and antibody 1493 (tab-delimited text file).
Additional file 4: The ChIP-on-chip results obtained using estrogen-
deprived then beta-estradiol stimulated cells and antibody 1.1 (tab-
delimited text file).
Additional file 5: The ChIP-on-chip results obtained using estrogen-
deprived then beta-estradiol stimulated cells and antibody 1493
(tab-delimited text file).
Additional file 6: The merged ChIP-on-chip data with the gene
annotations (tab-delimited text file). The raw ChIP on chip data has
been deposited in the NCBI GEO database (GEO:GSE18706).
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